Semnan University of Medical Sciences

Research and Technology Vice Chancellor

Salek Farrokhi, A. and Darabi, N. and Yousefi, B. and Askandar, R.H. and Shariati, M. and Eslami, M. (2019) Is it true that gut microbiota is considered as panacea in cancer therapy? Journal of Cellular Physiology. ISSN 00219541

Full text not available from this repository.


Recent studies demonstrated that a combination of the gut microbiome has the vital effect on the efficacy of anticancer immune therapies. Regulatory effects of microbiota have been shown in different types of cancer therapies such as chemotherapy and immunotherapy. Immune-checkpoint-blocked therapies are the recent efficient cancer immunotherapy strategies. The target of immune-checkpoint blocking is cytotoxic T lymphocyte protein-4 (CTLA-4) or blockade of programmed death-1 (PD-1) protein and its ligand programmed death ligand 1 (PD-L1) that they have been considered as cancer immunotherapy in recent years. In the latest studies, it have been demonstrated that several gut bacteria such as Akkermansia muciniphila, Bifidobacterium spp., Faecalibacterium spp., and Bacteroides fragilis have the regulatory effects on PD-1, PD-L1, and CTLA-4 blocked anticancer therapy outcome. © 2019 Wiley Periodicals, Inc.

Item Type: Article
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medical Sciences > School of Medicine
Depositing User: Admin User
Date Deposited: 18 Mar 2019 13:47
Last Modified: 18 Mar 2019 13:47

Actions (login required)

View Item